Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

Details

Language :

English

ISSN :

0732183X

Volume :

41

Issue :

2

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

161156213

Full Text :

https://doi.org/10.1200/JCO.21.01281